March 16, 2021 6:52 AM
value
The British pharmacist AstraZeneca announced on Tuesday, March 16, 2021, an agreement with the United States for the transportation of 500,000 dose additional of a possible treatment against covid with antibodies, which, if authorized, could be protected by virus people who can’t be vaccine.
One release, the company explained that the pact with Department of Health and Human Services (HHS) and Department of Defense extends another October 2020 agreement by which the US received 100,000 initial doses of AZD7442 drug, with the option to purchase more in 2021 and is committed to supporting the final phase of Clinical studies.
(…)
With the additional 500,000 doses announced on March 16 and another 100,000 given in parallel with Defense, AstraZeneca could provide Washington in 2021 up to 700,000 dose the drug, notes in the note.
“Combining antibodies with long-term effect has the potential to provide protection almost immediately for those who can not be vaccinated, both to prevent contagion to treat disease in already infected patients, “said pharmaceutical company CEO Pascal Soirot.
“Support US government is essential for accelerating the development of AZD7442, which we believe will be a instrument important in the fight against covid-19 “, he added.
The drug, which was designed to reduce resistance of the most powerful variants of the virus, it is currently evaluated in clinical trials with 9,000 volunteer in different parts of the world, the statement said.
AstraZeneca notes that the total value of agreements with the US government for development and pound of AZD7442 in 2021 amounts to approximately $ 726 million.